Global Cancer Cachexia Market Growth 2024, Forecast To 2033
11 Jul, 2024
The cancer cachexia market has shown strong growth, rising from $2.33 billion in 2023 to $2.47 billion in 2024 with a CAGR of 5.9%. Historical growth is attributed to advancements in understanding cancer biology, increasing prevalence of cancer cases, aging demographics globally, heightened focus on patient-centered care approaches, expansion of treatment options, and greater awareness among healthcare providers. Looking forward, the market is expected to maintain robust growth, projected to reach $3.14 billion by 2028 at a CAGR of 6.2%. Future growth drivers include heightened awareness about cachexia management, expanding geriatric population, adoption of novel therapeutic interventions, rising healthcare expenditures, and supportive government initiatives. Major trends in the forecast period encompass intensified research and development activities, diversification of therapeutic strategies, improved diagnostic capabilities, adoption of innovative treatment modalities, and advancements in supportive care practices.
Major Driver In The Cancer Cachexia Market
The growth of the cancer cachexia market is driven by the increasing prevalence of cancer, characterized by uncontrolled cell growth leading to tumor formation. Factors contributing to rising cancer cases include lifestyle changes, environmental factors, aging populations, genetic predisposition, improved diagnostic techniques, and heightened awareness prompting earlier medical consultations. Advances in medical technology and enhanced understanding of cancer facilitate earlier detection and reporting of cancer cachexia symptoms. For instance, in Australia, approximately 456,200 individuals were reported to have cancer in 2022, with around 151,000 new diagnoses in 2021, averaging 413 daily diagnoses. These statistics underscore the growing impact of cancer on healthcare systems and the consequent rise in demand for treatments targeting cancer cachexia. Therefore, the increasing prevalence of cancer is driving the growth of the cancer cachexia market.
Request A Free Sample Of The Global Cancer Cachexia Market ReportGlobal Cancer Cachexia Market Segmentation
The cancer cachexia market covered in this report is segmented –
1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics
2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions
3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies
By Geography:The regions covered in the cancer cachexia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The Cancer Cachexia Global Market Report 2024 furnishes information about the global cancer cachexia market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.
Cancer Cachexia Market Competitive Landscape
Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.
Purchase The Global Cancer Cachexia Market Report Directly And Get A Swift DeliveryCancer Cachexia Market Overview
Cancer cachexia is a metabolic syndrome characterized by progressive weight loss, muscle wasting, weakness, and loss of appetite in cancer patients, affecting their quality of life and treatment tolerance.
Cancer Cachexia Global Market Report 2023 provides data on the global cancer cachexia market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The cancer cachexia market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.